Libivirumab Biosimilar - Research Grade

Human

HBV

>1mg/ml

IgG1 - kappa

CHO Cells

Exbivirumab Biosimilar - Research Grade (ICH5540), Lenvervimab Biosimilar - Research Grade (ICH5632), Libevitug Biosimilar - Research Grade (ICH5641), Tobevibart Biosimilar - Research Grade (ICH5931), Tuvirumab Biosimilar - Research Grade (ICH5950)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of libivirumab, supplied strictly for research use only (RUO). It is a fully human IgG1 kappa monoclonal antibody built around the binding specificity of the originator drug, which recognizes the hepatitis B virus surface antigen (HBsAg). It is not the clinical drug and is not intended for human or veterinary use. The analog is useful as a defined, reproducible reagent for studying antibody-mediated recognition and neutralization of HBV surface antigen, for building positive/isotype controls in binding and blocking assays, and as a tool in preclinical and in-vitro workflows such as ELISA, surface plasmon resonance, and neutralization panels. Because it targets a viral antigen rather than a host protein, it is also useful for antigen-capture, standardization of anti-HBs detection, and antibody-engineering or ADC/bispecific development pipelines. It is offered at research grade with low endotoxin (typically less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and can be supplied in bulk milligram-to-gram quantities to support scaled and repeated experiments requiring lot-consistent material. Hepatitis B virus (HBV) is a small enveloped, partially double-stranded DNA virus of the Hepadnaviridae family and a major cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma. Its envelope carries the hepatitis B surface antigen (HBsAg), expressed as large, middle, and small proteins that share the common S domain. HBsAg mediates viral attachment and entry, largely via the pre-S1 domain engaging the hepatocyte receptor sodium taurocholate co-transporting polypeptide (NTCP/SLC10A1). HBsAg also circulates in vast excess as non-infectious subviral particles, contributing to immune tolerance in chronic infection. Neutralizing antibodies against HBsAg (anti-HBs) block entry and mark protective immunity, which is why HBsAg is the basis of the hepatitis B vaccine. Antibodies recognizing conserved S-domain epitopes are of interest for broad neutralization across HBV genotypes.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Libivirumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Libivirumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Libivirumab biosimilar target?

A: It is a non-therapeutic biosimilar of Libivirumab used as a binding and neutralization reagent against HBV; for research use only.